Moderna and Merck's Melanoma Vaccine Succeeds in Phase 3

Moderna and Merck announced that their jointly developed personalized melanoma vaccine met its primary endpoint in a Phase 3 clinical trial. This development led to significant gains in both companies' shares, with Moderna rising 93% and Merck gaining 7%. The vaccine aims to reduce the risk of disease recurrence in patients with high-risk melanoma. The successful trial results are considered a major milestone in this field. The companies stated that the data will be presented at upcoming medical conferences and that discussions with regulatory authorities will begin. This development once again highlights the potential of personalized approaches in cancer treatment. This is not investment advice.

📊 MRNA — Piyasa Yorumu

▲ up · 65%

Moderna's melanoma vaccine has demonstrated Phase 3 success, serving as a significant catalyst for the company. The stock price has surged 103% in the last 24 hours, with RSI in overbought territory (94.9) and MACD strongly positive. Short-term upward momentum may continue, but there is a risk of profit-taking following overbought conditions and rapid gains. Therefore, the trend is upward, but confidence is moderate.

RSI 14

94.9

MACD

5.38

24h Δ

102.97%

📊 MRK — Piyasa Yorumu

▲ up · 65%

The news serves as a strong catalyst for MRK and could positively impact the stock. Technical indicators also support this view; the price is above both the 20-day and 50-day moving averages, and the MACD is positive. However, the RSI at 85 indicates overbought conditions, which could lead to a short-term pullback. Therefore, while the likelihood of continued upside is high, caution is warranted given the current overheating. In the short term, upward momentum may persist, but volatility could increase.

RSI 14

85.8

MACD

1.49

24h Δ

10.26%

Canlı Grafikler